Shionogi Pharma Co., Ltd.

NAGASE Specialty Materials (NSM) has appointed Abdul Aziz El Khatib as a buyer. The Chicago resident will focus on the industrial side of NSM, managing domestic purchasing and inventory for its Performance Chemical lines. A native of the United Arab Emirates, El Khatib’s family came to the United States a decade ago and settled in the western Chicago suburbs. While at DePaul University, he did an internship with NAGASE Specialty Materials, where he was hired after graduation. “Abdul demonstrated a passion to learn and grow with NSM,” said Ray Winkel, director, supply chain management. “He has excellent communication skills and a desire to take on and manage projects.” El Khatib is fluent in English, Arabic and French. Prior to joining the NAGASE team, he had work experience in a retail environment with Meijer, a Midwest-based grocery chain ranked No. 14 on Forbes’ list of America’s largest privately held companies. There, he not only gained valuable customer service experience, but also was tasked with forecasting and replenishing stock. “I’m working the entire supply chain from product ordering, shipping, delivery to NSM and ultimately to our customers,” said El Khatib. “NAGASE is a good fit. I had a very good introduction to logistics and supply chain through the pandemic as we had to deal with supply chain issues. Getting an item from point A to point B, in the fastest way possible, intrigued me.”

LAS VEGAS, Nov. 14, 2022 /PRNewswire/ -- HLTH Inc., the company behind HLTH, the world's number one event for healthcare innovation and ViVE, the premier event for digital health leaders, has today announced the launch of their inaugural event in Europe. HLTH Europe will take place June 18-20, 2024 at the Rai Convention Center in Amsterdam and will unite the European health ecosystem. Continue Reading HLTH Inc. Announces Launch of HLTH Europe HLTH's newest event has already garnered early support from key launch partners, including: Advisory Board, ANDHealth, Babylon Inc, Bayer G4A, Cognicum, dacadoo, Deloitte, Digital Health Connector, European Connected Health Alliance, firstminute capital, Galen Growth, Google Health, Inovalon, Ipsos, MDClone, Merative, MTIP, Optum International, Philips, Proximie, SHI International, and Startup Health. "HLTH Europe will unite the European healthcare ecosystem to tackle healthcare's most complex challenges and identify its most promising opportunities," said Jonathan Weiner, Founder, Chairman & CEO of HLTH Inc. "We believe that by bringing all sectors of healthcare together, we can catalyze change for good." HLTH, which celebrates its fifth year this year, has quickly become America's most important event for healthcare innovation. This year's event has broken all records, with over 2,500 CEOs attending the event taking place this week in Las Vegas, over 850 sponsors showcasing the technologies and solutions at the forefront of innovation in healthcare, over 1,000 startups attending and over 9,500 total attendees. HLTH Europe will be led by a team based in London, and will cover the issues most pertinent to the European ecosystem. It will also feature a hosted buyer programme, exhibit hall showcasing the latest technologies and healthcare solutions, and partner programming. As one of Europe's most connected cities, and with a world-class venue and event facilities, Amsterdam has been chosen as HLTH Europe's home. About HLTH At HLTH, we believe that by uniting the healthcare ecosystem, we can tackle healthcare's most complex challenges and catalyze change, for good. Founded in 2018, our flagship event, HLTH, unites over 10,000 healthcare leaders in Las Vegas each fall and has quickly become the US's number one event in healthcare innovation. What started as a successful event launch has blossomed into a full-fledged community that embraces the entire health ecosystem, which now includes three major annual events, HLTH, ViVE and from 2024, HLTH Europe; a suite of digital content of offerings, including HLTH GoLIVE Webinars, Announcement Spotlights,, the HLTH Matters blog and podcast; and the HLTH Foundation - a charitable organization working with the industry to close longstanding gaps in equity. Today, HLTH offers a comprehensive platform that supports our mission to gather the health community in curated, purposeful engagements that accelerate healthcare innovation. Media Contact: [email protected] SOURCE HLTH

The new superconducting cyclotron holds the capacity to generate a high-intensity proton beam of 1000 nA, which is claimed to be the highest level for a proton therapy system A view of the beam acceleration test of the superconducting cyclotron. (Credit: Sumitomo Heavy Industries, Ltd) Sumitomo Heavy Industries (SHI) has announced the development of a superconducting cyclotron for the next-generation proton therapy system. The company has carried out proton beam acceleration tests on its in-house developed superconducting cyclotron for the new proton therapy system under development. The generation of a high-intensity proton beam of 1,000 nA by the superconducting cyclotron is confirmed by SHI. The new superconducting cyclotron is a significant achievement for the company in the development process of the next-generation proton therapy system. According to the company, scanning irradiation is used in proton therapy in recent times, involving the scanning of thin proton beams as per the tumour’s shape to reduce damage to normal tissues and organs around the tumor. Irradiating a tumour in a short time and suppressing the movement caused by respiration is required to precisely treat tumours in the lungs and livers, using scanning irradiation. To accomplish a short irradiation time, scanning the proton beam at high intensity and ultra-high speed is crucial, stated the company. The company has developed a superconducting cyclotron that holds the capacity to generate a high-intensity proton beam of 1000 nA, which is claimed to be the highest level for a proton therapy system. SHI stated: “Conventionally, irradiating a tumor with a proton beam requires a long time. However, the newly developed superconducting cyclotron can increase the intensity of the proton beam more than three times and shorten the irradiation time to less than one-third.” “In addition, the use of superconducting magnets reduces the power consumption by 40%, making it possible to operate the proton therapy system at lower cost.” SHI is also planning to carry out beam tests in combination with the ultra high-speed scanning technology under development.